|
Market Closed -
Other stock markets
|
After hours 20:59:51 | |||
| 22.54 EUR | +1.71% |
|
22.31 | -1.02% |
| 08-04 | Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says | MT |
| 08-04 | GSK : JP Morgan gives a Sell rating | ZD |
| Market Cap | 76.75B 103B 89.52B 83.45B 145B 9,829B 147B 981B 385B 4,918B 388B 380B 16,287B | P/E 2026 * |
13.3x | P/E 2027 * | 11.6x |
|---|---|---|---|---|---|
| Enterprise Value | 94.75B 128B 111B 103B 179B 12,132B 181B 1,211B 475B 6,070B 479B 469B 20,105B | EV / Sales 2026 * |
2.79x | EV / Sales 2027 * | 2.58x |
| Free-Float |
92.75% | Yield 2026 * |
3.63% | Yield 2027 * | 3.82% |
Last Transcript: GSK plc
| 1 day | +0.68% | ||
| 1 week | -2.38% | ||
| Current month | +0.76% | ||
| 1 month | -3.05% | ||
| 3 months | +3.25% | ||
| 6 months | -6.47% | ||
| Current year | +7.33% |
| 1 week | 22.16 |  | 23.25 |
| 1 month | 21.84 | | 23.7 |
| Current year | 20.27 | | 26.02 |
| 1 year | 15.78 | | 26.02 |
| 3 years | 14.68 | | 26.02 |
| 5 years | 14.62 | | 27.13 |
| 10 years | 14.62 | | 27.52 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 31/12/2025 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 30/04/2023 |
| Chief Tech/Sci/R&D Officer | - | 30/11/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 05/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 31/12/2017 |
Jonathan Symonds
CHM | Chairman | 68 | 31/08/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.71% | -2.38% | - | - | 103B | |
| +4.86% | -3.32% | +52.73% | +157.63% | 995B | |
| +1.04% | -2.99% | +50.87% | +48.81% | 614B | |
| +0.98% | -6.49% | +24.00% | +63.77% | 431B | |
| +1.96% | -0.87% | +43.02% | +37.60% | 353B | |
| -0.11% | -4.56% | +31.59% | +39.73% | 293B | |
| +2.52% | -6.99% | +8.08% | +10.32% | 245B | |
| +4.57% | +5.21% | +35.91% | +61.24% | 210B | |
| -4.32% | -12.25% | -5.97% | -44.56% | 210B | |
| -2.58% | -0.73% | +17.16% | +63.33% | 168B | |
| Average | +1.24% | -5.02% | +28.60% | +48.65% | 390.92B | |
| Weighted average by Cap. | +2.07% | -5.89% | +36.85% | +72.73% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.97B 45.75B 39.62B 36.94B 64.13B 4,350B 64.85B 434B 170B 2,177B 172B 168B 7,209B | 35.63B 47.98B 41.56B 38.74B 67.26B 4,562B 68.01B 455B 179B 2,283B 180B 176B 7,560B |
| Net income | 5.78B 7.78B 6.74B 6.28B 10.91B 740B 11.03B 73.81B 28.97B 370B 29.22B 28.58B 1,226B | 6.6B 8.88B 7.69B 7.17B 12.45B 845B 12.59B 84.27B 33.08B 423B 33.36B 32.63B 1,400B |
| Net Debt | 17.99B 24.23B 20.98B 19.56B 33.97B 2,304B 34.34B 230B 90.22B 1,153B 91B 88.99B 3,818B | 15.09B 20.32B 17.6B 16.41B 28.49B 1,932B 28.81B 193B 75.68B 967B 76.33B 74.65B 3,202B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/08/26 | €22.54 | +1.71% | 250 |
| 04/08/26 | €22.16 | -0.72% | 300 |
| 03/08/26 | €22.32 | -0.22% | 677 |
| 31/07/26 | €22.37 | -2.74% | 332 |
| 30/07/26 | €23.00 | -1.29% | 40 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GS71 Stock
Select your edition
All financial news and data tailored to specific country editions
